HR 4101
Cancer Drug Parity Act of 2025
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 4:10 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Cancer Drug Parity Act of 2025, aims to ensure that people with cancer pay the same cost-sharing amounts for oral anticancer drugs as they do for similar drugs administered by a healthcare provider. It requires group health plans to treat oral anticancer medications with the same cost-sharing rules as intravenously administered drugs, with certain exceptions for medical necessity and clinical appropriateness. The bill also restricts plans from making changes that would increase out-of-pocket costs for these medications and includes a study to assess the impact of the changes on patient access and affordability.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Becca [D-VT-At Large] Balint
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.